26 HAROKMIM STREET, HOLON, L3
Reports First Quarter 2026 Results
Material disclosure
Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Reports Third Quarter 2025 Results
To Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Management's Discussion and Analysis of Results of Operations and Financial Condition
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
No filings found
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence